Noxopharm Limited (NOXOF)
USD 0.05
(0.0%)
USD 0.05
(0.0%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 | 1.28 Million AUD | 22.12% |
| 2023 | 1.05 Million AUD | -57.38% |
| 2022 | 2.47 Million AUD | -65.02% |
| 2021 | 7.07 Million AUD | -1.63% |
| 2020 | 7.19 Million AUD | 25.1% |
| 2019 | 5.75 Million AUD | 30.66% |
| 2018 | 4.4 Million AUD | 1119.07% |
| 2017 | 361.04 Thousand AUD | 21.62% |
| 2016 | 296.85 Thousand AUD | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q4 | 1.28 Million AUD | 0.0% |
| 2024 Q3 | 1.28 Million AUD | 121.88% |
| 2024 Q2 | 580.76 Thousand AUD | 16.27% |
| 2024 Q1 | 499.51 Thousand AUD | -52.66% |
| 2024 FY | 1.28 Million AUD | 22.12% |
| 2023 Q2 | 3.21 Million AUD | 7.77% |
| 2023 Q4 | 1.05 Million AUD | 9.67% |
| 2023 FY | 1.05 Million AUD | -57.38% |
| 2023 Q1 | 2.98 Million AUD | 20.45% |
| 2023 Q3 | 962.14 Thousand AUD | -70.06% |
| 2022 Q2 | 2.45 Million AUD | 0.0% |
| 2022 Q4 | 2.47 Million AUD | 8.55% |
| 2022 FY | 2.47 Million AUD | -65.02% |
| 2022 Q1 | 2.45 Million AUD | -65.37% |
| 2022 Q3 | 2.28 Million AUD | -6.94% |
| 2021 Q1 | 6.36 Million AUD | -11.5% |
| 2021 FY | 7.07 Million AUD | -1.63% |
| 2021 Q4 | 7.07 Million AUD | 0.0% |
| 2021 Q3 | 7.07 Million AUD | 11.15% |
| 2021 Q2 | 6.36 Million AUD | 0.0% |
| 2020 Q1 | 9.05 Million AUD | 57.53% |
| 2020 Q3 | 7.19 Million AUD | -20.58% |
| 2020 Q2 | 9.05 Million AUD | 0.0% |
| 2020 FY | 7.19 Million AUD | 25.1% |
| 2020 Q4 | 7.19 Million AUD | 0.0% |
| 2019 Q1 | 4.81 Million AUD | 9.46% |
| 2019 Q2 | 4.81 Million AUD | 0.0% |
| 2019 Q3 | 5.75 Million AUD | 19.37% |
| 2019 FY | 5.75 Million AUD | 30.66% |
| 2019 Q4 | 5.75 Million AUD | 0.0% |
| 2018 Q3 | 4.4 Million AUD | 357.78% |
| 2018 FY | 4.4 Million AUD | 1119.07% |
| 2018 Q1 | 961.46 Thousand AUD | 166.3% |
| 2018 Q2 | 961.46 Thousand AUD | 0.0% |
| 2018 Q4 | 4.4 Million AUD | 0.0% |
| 2017 Q1 | 152.15 Thousand AUD | -48.75% |
| 2017 Q4 | 361.04 Thousand AUD | 0.0% |
| 2017 Q3 | 361.04 Thousand AUD | 137.29% |
| 2017 FY | 361.04 Thousand AUD | 21.62% |
| 2017 Q2 | 152.15 Thousand AUD | 0.0% |
| 2016 FY | 296.85 Thousand AUD | 0.0% |
| 2016 Q4 | 296.85 Thousand AUD | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| Qrons Inc. | 1.48 Million USD | 13.441% |
| Northwest Biotherapeutics, Inc. | 74.92 Million USD | 98.28% |
| Capstone Therapeutics Corp. | 50.26 Million USD | 97.436% |
| Adynxx, Inc. | - USD | -Infinity% |
| Santhera Pharmaceuticals Holding AG | 59.01 Million USD | 97.816% |
| ProtoKinetix, Incorporated | 44.69 Thousand USD | -2783.063% |
| BioStem Technologies, Inc. | 15.9 Million USD | 91.898% |
| Evofem Biosciences, Inc. | 72.47 Million USD | 98.222% |
| Skye Bioscience, Inc. | 14.07 Million USD | 90.843% |
| Rebus Holdings, Inc. | 5.24 Million USD | 75.418% |
| Arch Therapeutics, Inc. | 9.46 Million USD | 86.387% |
| Burzynski Research Institute, Inc. | 27.43 Thousand USD | -4597.313% |
| Neon Bloom, Inc. | 1.22 Million USD | -5.089% |
| Nascent Biotech, Inc. | 808.79 Thousand USD | -59.325% |
| Acro Biomedical Co., Ltd. | 201.11 Thousand USD | -540.732% |
| Eiger BioPharmaceuticals, Inc. | 53.3 Million USD | 97.583% |
| Nanobac Pharmaceuticals, Incorporated | 9.58 Million USD | 86.552% |
| Institute of Biomedical Research Corp. | 421.56 Thousand USD | -205.672% |
| SQZ Biotechnologies Company | 50.03 Million USD | 97.425% |
| Intellipharmaceutics International Inc. | 12 Million USD | 89.269% |
| Propanc Biopharma, Inc. | 3.85 Million USD | 66.542% |
| Mesoblast Limited | 188.44 Million USD | 99.316% |
| Marizyme, Inc. | 26.67 Million USD | 95.169% |
| Genus plc | 485 Million USD | 99.734% |
| VioQuest Pharmaceuticals, Inc. | 5.84 Million USD | 77.945% |
| Pharming Group N.V. | 244.07 Million USD | 99.472% |
| Therapeutic Solutions International, Inc. | 2.01 Million USD | 35.894% |
| CNBX Pharmaceuticals Inc. | 2.51 Million USD | 48.79% |
| Nymox Pharmaceutical Corporation | 3.8 Million USD | 66.089% |
| ContraFect Corporation | 32.53 Million USD | 96.039% |
| PsyBio Therapeutics Corp. | 1.98 Million USD | 34.961% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 3.82 Million USD | 66.334% |
| IMV Inc. | 37.93 Million USD | 96.603% |
| AXIM Biotechnologies, Inc. | 11.77 Million USD | 89.059% |
| MultiCell Technologies, Inc. | 1617.67 USD | -79558.645% |
| ONE Bio Corp. | 27.49 Million USD | 95.313% |
| Accustem Sciences Inc. | 1.07 Million USD | -19.4% |
| RVL Pharmaceuticals plc | 77.41 Million USD | 98.335% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| EV Biologics, Inc. | 2.11 Million USD | 39.075% |
| Q BioMed Inc. | 8.13 Million USD | 84.156% |
| Emmaus Life Sciences, Inc. | 82.93 Million USD | 98.446% |
| Mosaic ImmunoEngineering Inc. | 5.14 Million USD | 74.959% |
| Biomind Labs Inc. | 1.49 Million USD | 14.013% |
| American Oriental Bioengineering, Inc. | 118.72 Million USD | 98.915% |
| Provectus Biopharmaceuticals, Inc. | 9.04 Million USD | 85.749% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Oncotelic Therapeutics, Inc. | 18.4 Million USD | 92.998% |
| GlobeStar Therapeutics Corporation | 1.43 Million USD | 10.13% |
| THC Farmaceuticals, Inc. | 142.09 Thousand USD | -806.868% |
| Curative Biotechnology, Inc. | 5.74 Million USD | 77.573% |
| GB Sciences, Inc. | 5.41 Million USD | 76.214% |
| Alpha Cognition Inc. | 7.16 Million USD | 82.015% |
| HST Global, Inc. | 593.59 Thousand USD | -117.087% |
| CSL Limited | 18.62 Billion USD | 99.993% |
| Wesana Health Holdings Inc. | 1.25 Million USD | -2.336% |
| Halberd Corporation | 728.71 Thousand USD | -76.833% |
| Enzolytics Inc. | 365.26 Million USD | 99.647% |
| Agentix Corp. | 2.51 Million USD | 48.672% |
| Resverlogix Corp. | 67.39 Million USD | 98.088% |
| Nuo Therapeutics, Inc. | 838.73 Thousand USD | -53.638% |
| MetaStat, Inc. | - USD | -Infinity% |
| argenx SE | 444.95 Million USD | 99.71% |
| Enzon Pharmaceuticals, Inc. | 1.71 Million USD | 24.818% |
| Endonovo Therapeutics, Inc. | 24.74 Million USD | 94.793% |
| RespireRx Pharmaceuticals Inc. | 11.9 Million USD | 89.174% |
| GeneThera, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | 3.66 Million USD | 64.842% |
| AVAX Technologies, Inc. | 3.99 Million USD | 67.734% |
| Zenith Capital Corp. | 27.56 Thousand USD | -4574.141% |
| Genscript Biotech Corporation | 1.32 Billion USD | 99.903% |
| Ember Therapeutics, Inc. | 238.65 Thousand USD | -439.951% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | 3.73 Million USD | 65.493% |
| WPD Pharmaceuticals Inc. | 680.83 Thousand USD | -89.27% |
| Cotinga Pharmaceuticals Inc. | 2.71 Million USD | 52.478% |
| Kadimastem Ltd | 3.5 Million USD | 63.234% |
| Helix BioMedix, Inc. | 66.92 Thousand USD | -1825.345% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Reve Technologies, Inc. | 464.69 Thousand USD | -177.301% |
| LadRx Corporation | 2.2 Million USD | 41.441% |
| Cell Source, Inc. | 15.8 Million USD | 91.848% |
| Regen BioPharma, Inc. | 5.45 Million USD | 76.389% |
| Regen BioPharma, Inc. | 5.45 Million USD | 76.389% |
| NovAccess Global Inc. | 7.86 Million USD | 83.607% |
| Affymax, Inc. | 8.87 Million USD | 85.474% |
| Itoco Inc. | 1.65 Million USD | 22.051% |
| Rasna Therapeutics, Inc. | 2.05 Million USD | 37.189% |
| Pathfinder Cell Therapy, Inc. | 6.04 Million USD | 78.697% |
| Mobile Lads Corp. | 1.31 Million USD | 1.894% |
| CytoDyn Inc. | 127.89 Million USD | 98.992% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | 41.79 Thousand USD | -2982.882% |
| NanoSphere Health Sciences Inc. | 1.56 Million USD | 17.733% |
| Alseres Pharmaceuticals, Inc. | 11.04 Million USD | 88.333% |
| SYBLEU INC | 681.41 Thousand USD | -89.109% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| ImmunoCellular Therapeutics, Ltd. | 6.1 Million USD | 78.882% |
| International Stem Cell Corporation | 5.27 Million USD | 75.581% |
| Bioxytran, Inc. | 3.24 Million USD | 60.344% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | 625.8 Thousand USD | -105.912% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | 4.61 Million USD | 72.091% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 40.99 Million USD | 96.857% |
| Adhera Therapeutics, Inc. | 22.26 Million USD | 94.212% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | 2.02 Million USD | 36.377% |
| Innovation Pharmaceuticals Inc. | 5.47 Million USD | 76.477% |
| Neutra Corp. | 973.52 Thousand USD | -32.365% |
| Windtree Therapeutics, Inc. | 29.01 Million USD | 95.559% |
| PureTech Health plc | 125.58 Million USD | 98.974% |
| Coeptis Therapeutics, Inc. | 3.75 Million USD | 65.702% |
| IXICO plc | 1.9 Million USD | 32.189% |
| IntelGenx Technologies Corp. | 20.52 Million USD | 93.723% |
| Gelesis Holdings, Inc. | 103.32 Million USD | 98.753% |
| CSL Limited | 18.62 Billion USD | 99.993% |
| Cellectis S.A. | 249.36 Million USD | 99.483% |